Phase II study of weekly 4′-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: An EORTC Gynaecological Cancer Cooperative Group Study

Abstract In this study 24 patients with metastatic cervical cancer were treated with a weekly bolus injection of 4′-epidoxorubicin at a dose of 12.5 mg/m 2 . All patients were followed until disease progression. Toxicity was generally absent or very mild. Only 1 patient (4%) had a partial remission lasting 23 weeks and 9 patients (38%) had stable disease with a median duration of 13 weeks (range 7–36). 4′-Epidoxorubicin at this dose and schedule is not active in metastatic squamous cell carcinoma of the cervix.